| DNA methylation-based classification of central nervous system tumours D Capper, DTW Jones, M Sill, V Hovestadt, D Schrimpf, D Sturm, ... Nature 555 (7697), 469-474, 2018 | 2631 | 2018 |
| Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate L Bunse, S Pusch, T Bunse, F Sahm, K Sanghvi, M Friedrich, D Alansary, ... Nature medicine 24 (8), 1192-1203, 2018 | 494 | 2018 |
| ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma C Zhang, MC Burger, L Jennewein, S Genßler, K Schönfeld, P Zeiner, ... Journal of the National Cancer Institute 108 (5), djv375, 2016 | 402 | 2016 |
| EGFR heterogeneity and implications for therapeutic intervention in glioblastoma E Eskilsson, GV Røsland, G Solecki, Q Wang, PN Harter, G Graziani, ... Neuro-oncology 20 (6), 743-752, 2018 | 306 | 2018 |
| Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy GD Maurer, DP Brucker, O Bähr, PN Harter, E Hattingen, S Walenta, ... BMC cancer 11, 1-17, 2011 | 287 | 2011 |
| SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes D Bojkova, JUG Wagner, M Shumliakivska, GS Aslan, U Saleem, ... Cardiovascular research 116 (14), 2207-2215, 2020 | 267 | 2020 |
| The neurovascular unit as a selective barrier to polymorphonuclear granulocyte (PMN) infiltration into the brain after ischemic injury G Enzmann, C Mysiorek, R Gorina, YJ Cheng, S Ghavampour, ... Acta neuropathologica 125, 395-412, 2013 | 240 | 2013 |
| DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management F Nassiri, Y Mamatjan, S Suppiah, JH Badhiwala, S Mansouri, S Karimi, ... Neuro-oncology 21 (7), 901-910, 2019 | 236 | 2019 |
| CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy MC Burger, C Zhang, PN Harter, A Romanski, F Strassheimer, C Senft, ... Frontiers in immunology 10, 2683, 2019 | 202 | 2019 |
| CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas P Sievers, T Hielscher, D Schrimpf, D Stichel, DE Reuss, AS Berghoff, ... Acta neuropathologica 140, 409-413, 2020 | 192 | 2020 |
| Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated SLN Maas, D Stichel, T Hielscher, P Sievers, AS Berghoff, D Schrimpf, ... Journal of clinical oncology 39 (34), 3839-3852, 2021 | 186 | 2021 |
| Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma A Scholz, PN Harter, S Cremer, BH Yalcin, S Gurnik, M Yamaji, ... EMBO molecular medicine 8 (1), 39-57, 2016 | 169 | 2016 |
| Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence LM Katz, T Hielscher, B Liechty, J Silverman, D Zagzag, R Sen, P Wu, ... Acta neuropathologica 135, 955-963, 2018 | 159 | 2018 |
| MYCN amplification drives an aggressive form of spinal ependymoma DR Ghasemi, M Sill, K Okonechnikov, A Korshunov, S Yip, PW Schutz, ... Acta neuropathologica 138, 1075-1089, 2019 | 153 | 2019 |
| Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas F Fack, H Espedal, O Keunen, A Golebiewska, N Obad, PN Harter, ... Acta neuropathologica 129, 115-131, 2015 | 153 | 2015 |
| Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas PS Zeiner, C Preusse, A Golebiewska, J Zinke, A Iriondo, A Muller, ... Brain pathology 29 (4), 513-529, 2019 | 152 | 2019 |
| Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology D Capper, D Reuss, J Schittenhelm, C Hartmann, J Bremer, F Sahm, ... Acta neuropathologica 121, 241-252, 2011 | 152 | 2011 |
| Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases PN Harter, S Bernatz, A Scholz, PS Zeiner, J Zinke, M Kiyose, S Blasel, ... Oncotarget 6 (38), 40836, 2015 | 146 | 2015 |
| EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation E Eskilsson, GV Rosland, KM Talasila, S Knappskog, O Keunen, ... Neuro-oncology 18 (12), 1644-1655, 2016 | 126 | 2016 |
| MIF Receptor CD 74 is Restricted to Microglia/Macrophages, Associated with a M 1‐Polarized Immune Milieu and Prolonged Patient Survival in Gliomas PS Zeiner, C Preusse, AE Blank, C Zachskorn, P Baumgarten, L Caspary, ... Brain pathology 25 (4), 491-504, 2015 | 120 | 2015 |
